SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
So, the natural question for Regulus Therapeutics (NASDAQ:RGLS) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual ...
Results that may be inaccessible to you are currently showing.